324 related articles for article (PubMed ID: 33262028)
41. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
[TBL] [Abstract][Full Text] [Related]
42. Loss of bacillus Calmette-Guérin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette-Guérin exposure.
Shah G; Zhang G; Chen F; Cao Y; Kalyanaraman B; See W
J Urol; 2014 Mar; 191(3):823-9. PubMed ID: 24035882
[TBL] [Abstract][Full Text] [Related]
43. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
44. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
45. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.
Nishiyama N; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Kitamura H; Masumori N
Urol Oncol; 2018 Jun; 36(6):306.e9-306.e15. PubMed ID: 29550096
[TBL] [Abstract][Full Text] [Related]
46. Strategies for optimizing bacillus Calmette-Guérin.
Shah JB; Kamat AM
Urol Clin North Am; 2013 May; 40(2):211-8. PubMed ID: 23540779
[TBL] [Abstract][Full Text] [Related]
47. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
48. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward?
Zuiverloon TC; Zwarthoff EC
Eur Urol; 2016 Feb; 69(2):201-2. PubMed ID: 26209036
[No Abstract] [Full Text] [Related]
49. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
Kawai K; Miyazaki J; Joraku A; Nishiyama H; Akaza H
Cancer Sci; 2013 Jan; 104(1):22-7. PubMed ID: 23181987
[TBL] [Abstract][Full Text] [Related]
50. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
51. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
de Jong FC; Hoedemaeker RF; Kvikstad V; Mensink JTM; de Jong JJ; Boevé ER; van der Schoot DKE; Zwarthoff EC; Boormans JL; Zuiverloon TCM
J Urol; 2021 Mar; 205(3):701-708. PubMed ID: 33191862
[TBL] [Abstract][Full Text] [Related]
52. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
[TBL] [Abstract][Full Text] [Related]
53. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
54. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
Alexandroff AB; Nicholson S; Patel PM; Jackson AM
Immunotherapy; 2010 Jul; 2(4):551-60. PubMed ID: 20636008
[TBL] [Abstract][Full Text] [Related]
55. Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer.
Danişman A; Bulut K; Kukul E; Ozen I; Sevük M
Urol Int; 2000; 64(4):198-201. PubMed ID: 10895085
[TBL] [Abstract][Full Text] [Related]
56. An unusual cause of retention of urine after intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer.
Cheung JM; Hou SS; Yip SK; Ng CF
Hong Kong Med J; 2011 Dec; 17(6):492-4. PubMed ID: 22147321
[TBL] [Abstract][Full Text] [Related]
57. Can random bladder biopsies be eliminated after bacillus Calmette-Guérin therapy against carcinoma in situ?
Takamatsu K; Matsumoto K; Kikuchi E; Ogihara K; Hayakawa N; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Asanuma H; Mikami S; Oyama M; Oya M
Int Urol Nephrol; 2021 Mar; 53(3):465-469. PubMed ID: 33025406
[TBL] [Abstract][Full Text] [Related]
58. Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201-2: The Goal: Individualized Bacillus Calmette-Guérin Therapy.
Kamat AM; Urbauer DL
Eur Urol; 2016 Feb; 69(2):203. PubMed ID: 26260001
[No Abstract] [Full Text] [Related]
59. γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria.
Noguera-Ortega E; Rabanal RM; Secanella-Fandos S; Torrents E; Luquin M; Julián E
J Urol; 2016 Jan; 195(1):198-205. PubMed ID: 26165584
[TBL] [Abstract][Full Text] [Related]
60. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
